This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of the Nutraceutical "Hemofix" on the Coagulation System

This study has been withdrawn prior to enrollment.
Yocheved Grossman
Idan Grossman
Information provided by (Responsible Party):
Hadassah Medical Organization Identifier:
First received: July 25, 2012
Last updated: February 22, 2017
Last verified: February 2017
Hemofix is a herbal formula based on traditional Jewish and far eastern medicine created to assist in wound healing and bleeding arrest. It contains herbs such as Red Clover, Liquorice, Raspberry, Ginger and more. The present study will evaluate the formula on the coagulation system.

Condition Intervention
Von Willebrand Disease Menorrhagia Dietary Supplement: HEMOFIX

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Phase 1 Study of the Nutraceutical "Hemofix" Safety and Effect on the Coagulation System

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • bleeding and blood test results [ Time Frame: one year ]

Enrollment: 0
Study Start Date: September 2016
Estimated Study Completion Date: December 2023
Estimated Primary Completion Date: January 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HEMOFIX
3 grams a day
Dietary Supplement: HEMOFIX
unique complex herbal mixture


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers and volunteers with a mild bleeding disorder

Exclusion Criteria:

  • people with thrombophilic and cardiovascular complications,
  • people who are treated with anti-coagulants,
  • women taking birth control pills
  • people with a history hypercoagulability
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01651468

Hadassah Medical Organization
Jerusalem, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Yocheved Grossman
Idan Grossman
Principal Investigator: David Varon, Prof HMO
  More Information

Responsible Party: Hadassah Medical Organization Identifier: NCT01651468     History of Changes
Other Study ID Numbers: HEMOFIX- HMO-CTIL
Study First Received: July 25, 2012
Last Updated: February 22, 2017

Keywords provided by Hadassah Medical Organization:
mild bleeding disorder

Additional relevant MeSH terms:
Von Willebrand Diseases
Uterine Hemorrhage
Uterine Diseases
Genital Diseases, Female
Menstruation Disturbances
Pathologic Processes
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Blood Platelet Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn processed this record on September 21, 2017